Target intelligence / Profile preview

ATP-sensitive potassium channel (vascular type) (KATP channel)

Target
KATP channel
Molecular classification
Ion channel, Inward-rectifier potassium channel complex, ABC transporter-complexed channel
01

Overview

ATP-sensitive potassium channels (vascular type) are hetero-octameric complexes formed by inward-rectifier potassium channel subunits (primarily Kir6.1 encoded by KCNJ8) and regulatory sulfonylurea receptor subunits (type SUR2B, encoded by ABCC9), localized predominantly within vascular smooth muscle[1][4]. These channels link cellular metabolic state—reflected by the ATP/ADP ratio—to the cell’s membrane potential: they are inhibited by intracellular ATP and activated by ADP, leading to hyperpolarization of the smooth muscle membrane when open, which decreases Ca2+ influx and induces vasodilation[4][1][5]. Vascular KATP channels play key roles in blood pressure regulation and protection against ischemic injury[1], and are important drug targets for antihypertensive vasodilators (e.g., minoxidil, diazoxide) as well as side-effect targets for sulfonylurea antidiabetic drugs[4][1].

Other names
Vascular KATP channelVascular ATP-sensitive K+ channelKir6.1/SUR2B channelPotassium inwardly-rectifying channel subunit Kir6.1-Sulfonylurea receptor 2B complex
02

Mechanism of action

Channel blockers inhibit KATP channel activity, increasing membrane excitability, and can constrict vessels. Channel openers activate KATP channels, leading to membrane hyperpolarization, reducing Ca2+ influx, and causing vasodilation[4][1].

03

Biological functions

Regulation of vascular toneMembrane potential modulation in vascular smooth muscleCoupling of cellular metabolism to excitabilityVasodilation and regulation of blood flow
04

Disease associations

Cardiovascular diseaseIschemia/reperfusion injuryHypertensionOther vascular disorders
05

Safety considerations

Channel openers may cause excessive hypotension, edema, and reflex tachycardia[4][1].Channel blockers can increase cardiovascular risk in some contexts, such as by raising blood pressure or predisposing to ischemic damage[4].
06

Interacting drugs

Sulfonylureas (e.g., glibenclamide, glimepiride) [blockers]

1 more in the full profile.

07

Biomarkers

Genetic variants in KCNJ8 (Kir6.1) or ABCC9 (SUR2B), associated with vascular channelopathies.Expression levels of channel subunits in vascular tissue (investigational)

Beyond the preview

Go deeper on ATP-sensitive potassium channel (vascular type) (KATP channel).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP-sensitive potassium channel (vascular type) (KATP channel).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call